Blink Science joins the Good Health Pass Collaborative

The open, inclusive, cross-sector initiative will create a blueprint for interoperable digital health pass systems that will help restore international travel and restart the global economy.

ATLANTA (March 23, 2021) – Blink Science, Inc., a company dedicated to revolutionizing global point-of-care medical diagnostics, has partnered with the Good Health Pass Collaborative.

Launched by ID2020 in February, the Good Health Pass Collaborative is an open, inclusive, cross-sector initiative which aims to create a blueprint for interoperable digital health pass systems as a means to safely restore international travel, resume public life, and restart the global economy.

Good Health Pass

In joining the Collaborative, Blink Science, a unique and innovative medical diagnostics and technology startup, joins global giants including Clear, the Commons Project Foundation, COVID-19 Credentials Initiative (CCI), IBM, International Chamber of Commerce (ICC), Linux Foundation Public Health, Mastercard, and Salesforce to jointly articulate principles and develop technical standards for digital health pass systems that are privacy-protecting, user-controlled, equitable, and interoperable.

In February, the Collaborative released its first white paper, entitled Good Health Pass: A Safe Path to Global Reopening, which outlines these principles. Over the next three months, the Collaborative plans to release at least two additional publications; the Good Health Pass Interoperability Blueprint, and the Good Health Pass Governance Framework Recommendations.

Digital health passports will allow users to retrieve their health credentials online, in print, or on a mobile device by linking an individual’s identity to a test result or vaccination certificate to enable real-time, fraud resistant digital verification. blinkPASSPORT™ and blinkVERIFY™ are a passport system that registers vaccinations, as well as testing information, within a HIPAA compliant app, and provide verification when an individual has been vaccinated and/or tested.

“Most of the vaccination passports available to-date are ignoring one very key element– the need for fast and reliable testing. Until vaccines are able to provide reliable resistance to the many COVID variants and are universally available for every person in the world, widespread testing will remain essential to safely return to public life,” expressed Blink Science President Eric Doherty.

Blink Science is in the process of pursuing FDA Emergency Use Authorization for blinkTEST™, a handheld point-of-care (POC) diagnostic testing platform that allows for rapid, sensitive detection and quantification of SARS-CoV-2 from a small saliva sample.

To be successful in bringing the pandemic to an end, this global effort requires that solutions be designed to be interoperable with one another and across institutional and geographic borders.

“Fragmentation is a risk we simply cannot ignore. To be valuable to users, credentials need to be accepted at check-in, upon arrival by border control agencies, and more,” said Dakota Gruener, ID2020 Executive Director. “We can get there – even with multiple systems – as long as solutions adhere to open standards and participate in a common governance framework. But without these, fragmentation is inevitable, and travelers – and the economy – will continue to suffer needlessly as a result. We are delighted to welcome Blink Science to the Collaborative and look forward to working with them in the coming months. ”


About ID2020

ID2020 is a global public-private partnership that harnesses the collective power of nonprofits, corporations, and governments to promote the adoption and ethical implementation of user-managed, privacy-protecting, and portable digital identity solutions.

By developing and applying rigorous technical standards to certify identity solutions, providing advisory services, and implementing programs, and advocating for the ethical implantation of digital ID, ID2020 is strengthening social and economic development globally.

ID2020 Alliance partners are committed to a future in which all of the world’s seven billion people can fully exercise their basic human rights and reap the benefits of economic empowerment and to protecting user privacy, and ensuring that data is not commoditized.

ID2020 and Good Health Pass Collaborative Media Contact:
Ethan Veneklasen

CEO|CFO Magazine Interviews Billy Meadow & Eric Doherty of Blink Science

CEOCFO: Mr. Meadow, what is the concept behind Blink Science?

Mr. Billy Meadow, Chairman: Blink Science was formed when we licensed an amazing innovation from the University of Florida for an electro chemical biosensor that can be produced like a diabetic glucose strip. This technology will enable a transformation of diagnostics and a wide variety of disease indications. It involves a glucose strip and a handheld detection device we call blinkTEST COVID. This particular technology has direct ramifications on high-volume testing for COVID, so our company has a huge opportunity in front of us to help resolve the pandemic with extreme high-level testing.

Mr. Eric Doherty CEO: From our standpoint it is our way to enter the marketplace and make a huge impact on worldwide Point of Care (POC) diagnostic healthcare. From a global standpoint, Blink Science’s mission is to be a global diagnostic medical device organization, not only for COVID but also for a number of other disease states like tuberculosis, oncology, and your typical infectious diseases like strep and flu. We are entering into the healthcare market with COVID and then broadening our testing applications to more than 50 additional assays.  

CEOCFO: How does it work, why does it work, and has it been tried in some form before?  

Mr. Doherty: The research work was completed at the University of Florida. The UF Research team initially started their research on troponin, which is a biomarker for heart attacks. They then moved over to the Zika virus. Last spring, when COVID hit, they started developing research technology on COVID. In September, we licensed the Intellectual Property and Patent Rights from the University of Florida. It is because it is new technology that can be mass produced, like glucose strips are made today, but with enhanced technology embedded in the strip.

The COVID tests that you are hearing about in the new today are in most cases PCR tests. Those tests are heterogeneous tests. They typically use different chemicals, different solutions, and different temperature gradients needed for each test. Our blinkTEST is a homogenous type of test. In seconds, like flipping a light switch, you get a result, whereas the PCR tests can take anywhere between five, ten, fifteen or more minutes to give a result.

CEOCFO: Is it a yes, no, negative or positive? Is there a gradation of the result?

Mr. Doherty: It will provide instant results, in seconds, whether or not a patient has COVID. The key differences-and the biggest benefits-are twofold. Number one, there are minimal false positive tests. Going back to the relationship between a heterogeneous and homogenous type of testing application, the homogenous tests reduce the number of false positives because they do not rely on solutions, chemicals, or temperature needs that can vary a result. Through the University of Florida research on COVID, they were able to show a sensitivity range of 98% and a specificity range of 98%. Through the work that we are currently doing, we are looking to increase both the sensitivity and specificity.

CEOCFO: Is the science accepted and does the medical community understand this type of technology? What has been the response from people that may know what you are working on now?

Mr. Doherty: Because the manufacturing process is similar to the diabetic glucose strip industry, there are many similarities. Our handheld device, blinkTEST, is a comparable device to the diabetic glucose strip reader. When the medical community understands that the technology is in the strip, and understands the speed of the test, and the reliability of the results, they will want to use this test to diagnose all of their suspect COVID patients.

CEOCFO: What medium would you be testing and what can you test in the future?

Mr. Doherty: The Blink Science Platform is fluid-based. The testing platform can use any type of fluid. In this case, we are taking saliva, but with other tests it may vary. The medium depends on the test. Because of the sensitivity that we will be able to get with this type of test, we will lean towards saliva; but for other markers, other assays, we may use blood or urine. From a non-healthcare application, there are also many options in the food industry, agriculture, pet and livestock industries, where our Blink Science Platform could be used. We could use our strips to test food and ingredients. In agriculture, we could test water, and chemicals being used. In the pet and livestock markets, we could test for all sorts of animal infectious diseases.

CEOCFO: What is the product? Is there a device and various strips? What are the components that someone would need to administer the test?

Mr. Doherty: blinkTEST COVID can be handheld or placed on a desktop or a clinic bench top. It is the size of a mobile phone. The blinkSTRIPs are very similar in configuration to glucose strips. You place the strip into the device and push the button. That’s it. It will instantly give a readout. Green means go, that you do not have COVID. A red X shows you do have COVID. In the event you receive a red X, we recommend that you follow the current CDC guidelines.

CEOCFO: Blink Science is aiming at a global market. Are there particular areas that you see the ability to enter first or easier?

Mr. Doherty: We will be filing two Emergency Use Authorization’s (EUA’s) with the FDA. We will be filing the first EUA for healthcare provider usage and the other for at-home use. We will also be filing for a CE designation which is the European Union designation. We will also file for a Health Canada approval. We are looking at saturating the globe with blinkTEST COVID’s and blinkSTRIPs to help end the Pandemic. We do not want another person to die from COVID. We will be entering into the EU, APAC, NORAM, and LATAM markets.

CEOCFO: Are you funded for your next steps?

Mr. Meadow: We have been funded to date by me and some other angel investors. Frankly, our entire team of 47 is taking very little salary and taking classic sweat equity because we are all committed to using this technology to help put the pandemic behind. Even with the vaccine being available there still will be the need for large scale testing. We have a fundamental technology that can do that and we have a tremendously dedicated team working full throttle to get there. We are currently looking for additional capital rounds, but we think we will be able to generate significant revenue from our customers who are lined up to acquire our technology and license our software.

Mr. Doherty: We have a second vertical that is on the IT healthcare side called blinkPASSPORT, that will be available in February. blinkPASSPORT is a passport system that registers vaccinations, as well as testing information within a HIPAA compliant app. With the vaccination rollout, there have been a lot of issues such as slow distribution, side effects, and vaccination suspensions due to not working against the new UK variant. There will be ongoing reasons that testing will need to continue to be done. One, there are a lot of people who still have not been vaccinated. Two, some people will not be vaccinated because they do not want to be. And, lastly, those who cannot be vaccinated because of health issues: either they are pregnant, or they have other underlying health issues which prohibit them from being able to get vaccinated. All of the so-called vaccination passports are missing one very key element. The need for testing. We will be the only provider of instant testing. We will be capturing data from large testing organizations, like Labcorp and Quest Diagnostics, as well as other testing providers-like a Walgreens, CVS, Walmart, etc.-that is doing testing and be able to push that up into a cloud-based system. This, along with vaccination data, will allow for a true, authentic entry passport, that no other entity will have.  

CEOCFO: So many companies are involved in different aspects related to COVID, why are you confident even though it is a game-changing technology, that you will be able to get the traction and interest Blink deserves?

Mr. Doherty: We do not have a demand issue. Who does NOT need to be tested? I have never seen demand like we are seeing with this technology and it revolves around two things. One is that we have the potential to deliver an extremely large volume of testing devices and strips so that we can meet the testing needs of all the healthcare organizations in the US, and the world. Number two, blinkTEST COVID will provide instantaneous results. If someone needs to come into a facility and cannot wait in line for fifteen or twenty minutes for test results to come back, that individual can get tested and have a result provided in seconds, and then enter the venue safely.

There is nothing quite like it. People who are currently spending tons of money on different tests, should recognize that.   

CEOCFO: You seem to have manufacturing lined up. Where are you manufacturing? How will you have the capacity should everyone jump on board the way they should?

Mr. Doherty: Our whole initiative is to keep as much of the manufacturing based here in the US. Because of the high volumes needed for the blinkSTRIPs and blinkTEST COVID devices, we may need to go outside of the US for volume production needs.

We have already enlisted help from largest healthcare distribution organization in the world. We are also in the process of enlisting the help of the largest shipping organization in the world to ship out our product globally, on EUA approval, overnight. We have put plans in place so that once we get that approval through the FDA’s EUA, we will be able to get this out into the US marketplace rapidly to help squash this epidemic. As we get the other global approvals, the same distribution will occur. Rapid global distribution.

CEOCFO: What do you understand about working with the FDA?

Mr. Doherty: This is something that the FDA is asking for-rapid and reliable instant COVID testing. They want the fastest test that they can get for COVID, and we are going to bring to them that solution. It becomes more of a question of how what data we can provide to the FDA.  We are looking to provide them data that is specific, sensitive, and reliable. As long as we have that I think we are going to be in great shape with the FDA.

CEOCFO: What have you learned along the way that may have surprised you in the process of getting to where Blink is right now?

Mr. Meadow: I would say the eagerness of people in business in these large corporations that we are working with. They are open to changing their business modalities to help us accelerate the deployment of this technology. When we need something done right away, they jump right on it and we are seeing that across the board. We are seeing tremendous cooperation and collaboration.

You are also seeing that in the Commons Project (CommonPass for air travel) and the vaccination committees where companies like Oracle, IBM, Salesforce, and Microsoft are all collaborating to put data together so that we can get the world back to normal. We are seeing it with all the manufacturers and suppliers and everybody we are working with. It is a good thing. A lot of people know that testing is going to resolve the problem more so than just vaccination.

CEOCFO: Final thoughts?

Mr. Doherty: I was just going to add to Billy’s commentary. As he mentioned earlier, we have not run into anybody that does not want to help. I think from that standpoint, that is a game-changer for us. We are a very unique startup, and we are talking to some of the largest corporations in the world like, Oracle, Microsoft, IBM Watson. They are willing and able to help. And-like us-they want to help end the pandemic. That is our collective goal. Obviously to grow the business with our tests that have come down the line: but we want to make a huge splash with Blink Science on the global front and to be the diagnostic company that helps end this deadly pandemic.

To Ensure a Rapid Entry to Market with its Revolutionary Instant COVID-19 Testing Platform, Blink Science Inc. Adds to its Technology Team

Blink Science adds Chuck Harvey as CIO and Emmanuel Diserbeau as Head of Blink Science IT Architecture and Engineering.

ATLANTA, Jan. 26, 2021 /PRNewswire/ —Blink Science, Inc. a company dedicated to revolutionizing global point-of-care medical diagnostics, has added two key individuals to their leadership team.

Chuck Harvey joins Blink Science as Chief Information Officer. With more than 30 years of IT and technology experience, Harvey dedicated the past two decades to leading IT and engineering functions for Boost Mobile, Cricket Wireless and Nuvectra Medical as the CIO/CTO. As CIO for medical device start-up Nuvectra Medical, Harvey created and managed IT, helping make them an independently managed, publicly traded company. His experience includes leading the delivery of all enterprise platforms, leading engineering efforts focused on driving improved patient outcomes, and building and managing the cyber-security strategies to enable the company to operate in the highly regulated medical device industry, including HIPAA readiness. Chuck defined and deployed the organizational strategy for the company’s technology function, hired the team to deliver across his IT services model, and built award-winning mobile, web and cloud-based technology products.

Emmanuel Diserbeau joins Blink Science as Head of IT Architecture and Engineering. Emmanuel brings more than 15 years of advanced technical expertise in technology architecture and engineering. His background includes building award-winning technology products across mobile, web and cloud deployments. 

To Ensure a Rapid Entry to Market with its Revolutionary Instant COVID-19 Testing Platform, Blink Science, Inc. adds CIO

Emmanuel is passionate about technology and has been innovating technology solutions in the medical device space for the past five years. He is an expert in designing, building and deploying software and hardware solutions that have driven improved patient outcomes. Emmanuel will lead solutions architecture and engineering across the Blink Science technology stack. He will work closely with our technology teams to build solutions across mobile, web and cloud to enable Blink Science to scale quickly with high-availability and high-performing architectures.

Eric Doherty, Blink Science President, stated, “I am excited to welcome Chuck Harvey and Emmanuel Diserbeau to our innovative team. Their contributions will factor greatly in our ability to bring our incredible new diagnostic testing technology to market quickly, along with providing the strong architecture needed for blinkPASSPORT and blinkVerify to the public and corporate sectors.  We are looking to be a part of The Commons Project coalition, and the Vaccination Credential Initiative to help develop the needed standards within the healthcare passport programming.  Working with companies like Oracle, Microsoft, IBM Watson, and the Mayo Clinic, we will have the end-product these healthcare passports need: instant, reliable, testing results.” 

For investors interested in being part of the revolutionary technology, Blink Science welcomes conversations with corporations about funding their high-tech, low-cost point-of-care diagnostic tools. These tools have immediate application for COVID-19 but other forthcoming possible applications, too, including rapid testing for heart attacks and concussions as well as oncology diagnostics. Blink Science is in the process of pursuing FDA Emergency Use Authorization for blinkTEST, a handheld Point of Care (POC) diagnostic testing platform that allows for rapid, sensitive detection and quantification of SARS-CoV-2 from a small saliva sample.

About Blink Science
At Blink Science, we endeavor to bring high-tech, low-cost diagnostic tools to the global medical community. Our goal is to revolutionize point-of-care (POC) testing to ensure safe, fast, precise diagnosis and treatment for acute and chronic conditions that impact people throughout the world. This revolutionary test is set to change the world of diagnostic testing.

Test. Blink. Go.

Twitter @blinksci 
LinkedIn @blinksci

Media Contact:
Sandra McCollum
CEO/Brand Manager, Dash Brand Management 
(970) 217-6310

Press Release:

New Blink Science President to Lead Development of the World’s First Instant COVID POC Diagnostic Testing Device and Electronic Medical Passport

ATLANTA, Jan. 19, 2021 /PRNewswire/ — Blink Science, Inc., creator of instant diagnostic tools and innovative medical passport systems, announces the appointment of Eric Doherty as the company’s new president.  

Doherty joins Blink Science with nearly 30 years of healthcare executive leadership experience. He has held senior-level sales operations and marketing roles at leading healthcare companies such as GlaxoSmithKline, Abbott Laboratories, Uvanta Pharmacy Systems, AstraZeneca, and GLOCK International.

“I couldn’t be more passionate about Blink Science’s mission to bring high-quality, low-cost diagnostic testing to everyone,” Doherty said. “And our medical passport system, blinkPASSPORT, will keep life and commerce going as well as put people’s medical data in their own hands. We’ve got an exceptional team and culture here, and I’m proud to lead it.”

Doherty is passionate about Blink Science’s mission to bring high-quality, low-cost diagnostic testing to everyone.

Doherty continued, “From a global perspective, we are working with the world’s largest healthcare distributors and the world’s largest shipping and logistics organizations to ensure that once we receive an EUA for our device, we can ship it to the places that need it, immediately.  ZoomInfo has been a huge help in disseminating information about what Blink Science is working on, so we can help end this Pandemic.”

“Eric has just the right background and exceptional leadership skills to quickly make Blink Science a household name worldwide,” said Billy Meadow, Blink Science’s founder, CEO and board chair. “Our testing technology and data platforms will measurably improve the quality of life for billions of people—not just related to COVID but for many infectious diseases as well as other conditions where instant, portable diagnosis is critical. Eric will bring us to market in 2021.” 

Doherty holds MBA’s from both St. Louis University and Washington University in International Marketing and Management, and Global Operational Leadership Certification from St. Louis University.

About Blink Science
At Blink Science, we endeavor to bring high-tech, low-cost diagnostic tools to the global medical community. Our goal is to revolutionize point-of-care testing to ensure safe, fast, precise diagnosis and treatment for acute and chronic conditions that impact people throughout the world.

Test. Blink. Done.™

Twitter @blinksci 
LinkedIn @blinksci

Connect with Eric Doherty
Twitter @presblinksci 
LinkedIn @ericdoherty

CONTACT: Carlo De La Mata,

Press Release: